Clinical trial
Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
NCT07079696 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 1, 2025
- Completion date
- January 31, 2027
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
all-trans retinoic acid, autism spectrum disorder, dup15q syndrome, therapy